Investors & Media

SEC Filing Details

Document Details

Form
SC 13E3/A
Filing Date
Jun 17, 2022
Document Date
Jun 17, 2022
Form Description
Amendment to a previously filed SC 13E3
Filing Group
Other
Company
Entasis Therapeutics Holdings Inc.
Issuer
ENTASIS THERAPEUTICS HOLDINGS INC.

"Antibiotic resistance is a worldwide problem that is constantly growing. New forms of resistance can spread quickly and across continents. At Entasis, we discover and develop novel antibacterials to address the serious medical need posed by multi-drug resistant bacterial infections."

— Ruben Tommasi, Chief Scientific Officer